Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Fc-optimized monoclonal antibodies show superior efficacy


Monoclonal antibody (mAb) therapies have shown some use in patients with mild to moderate COVID-19, but have limited efficacy in preventing complications or death in patients with severe COVID-19. Reporting in Nature, Ravetch, Bournazos and colleagues now demonstrate that optimizing mAbs for the engagement of activating Fcγ receptors (FcγRs) significantly improves their ability to confer full protection in SARS-CoV-2 challenge models. Moreover, these mAbs are also highly potent at reducing mortality post-infection in animal models of severe COVID-19. These findings illustrate the importance of FcγR-mediated pathways in antibody-mediated antiviral immunity and have important implications for the development of more effective mAb therapeutics.


Original article

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alexandra Flemming.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Flemming, A. Fc-optimized monoclonal antibodies show superior efficacy. Nat Rev Immunol 21, 693 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing